Literature DB >> 4175542

Catabolism of human gammaG-immunoglobulins of different heavy chain subclasses. I. Catabolism of gammaG-myeloma proteins in man.

H L Spiegelberg, B G Fishkin, H M Grey.   

Abstract

The rates of catabolism of human gammaG-immunoglobulins of subclasses gammaG(1), gammaG(2), gammaG(3), and gammaG(4) were studied by determining the rates of elimination from the circulation of pairs of (131)I-and (125)I-labeled gammaG-myeloma proteins in 57 patients suffering from cancer other than multiple myeloma. On the average, gammaG(1)-, gammaG(2)-, and gammaG(4)-myeloma proteins were catabolized at a rate similar to that of normal gammaG-immunoglobulin, whereas gammaG(3)-myeloma proteins were catabolized more rapidly than normal gammaG-immunoglobulin. The average half-lives for the myeloma proteins were 12.3 days for normal gammaG, 11.6 days for gammaG(1), 12.4 days for gammaG(2), 8.2 days for gammaG(3), and 11.3 days for gammaG(4). However, significant differences in catabolic rates were observed when individual myeloma proteins of a single subclass were compared. These individual variations were present within all four heavy chain subclasses. The extent of differences ranged from 10 to 47%. The catabolic rate of normal gammaG was in an intermediate range when compared with myeloma proteins of relatively long and short half-lives. The rate of catabolism of an individual myeloma protein did not correlate with its light chain type, Gm factor, carbohydrate content, or electrophoretic mobility. These findings indicate that the structure(s) related to the catabolism of gammaG-immunoglobulins are complex and differ from one immunoglobulin molecule to another.

Entities:  

Mesh:

Substances:

Year:  1968        PMID: 4175542      PMCID: PMC297396          DOI: 10.1172/JCI105917

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  25 in total

1.  FACTORS CONTROLLING SERUM GAMMA-GLOBULIN CONCENTRATION.

Authors:  J L FAHEY; A G ROBINSON
Journal:  J Exp Med       Date:  1963-11-01       Impact factor: 14.307

2.  A new human gamma globulin factor determined by an allele at the Inv locus.

Authors:  A G STEINBERG; J A WILSON; S LANSET
Journal:  Vox Sang       Date:  1962       Impact factor: 2.144

3.  A new supporting medium for preparative electrophoresis.

Authors:  H J MULLER-EBERHARD
Journal:  Scand J Clin Lab Invest       Date:  1960       Impact factor: 1.713

4.  Nitrogen determination by a continuous digestion and analysis system.

Authors:  A FERRARI
Journal:  Ann N Y Acad Sci       Date:  1960-07-22       Impact factor: 5.691

5.  Heavy-chain subclasses of human gamma-G-globulin. Peptide and immunochemical relationships.

Authors:  H M Grey; H G Kunkel
Journal:  Biochemistry       Date:  1967-08       Impact factor: 3.162

6.  A method of trace iodination of proteins for immunologic studies.

Authors:  P J McConahey; F J Dixon
Journal:  Int Arch Allergy Appl Immunol       Date:  1966

7.  Biologic activities of aggregated gamma-globulin. 8. Aggregated immunoglobulins of different classes.

Authors:  T Ishizaka; K Ishizaka; S Salmon; H Fudenberg
Journal:  J Immunol       Date:  1967-07       Impact factor: 5.422

8.  The transmission of immunity from mother to young and the catabolism of immunoglobulins.

Authors:  F W Brambell
Journal:  Lancet       Date:  1966-11-19       Impact factor: 79.321

9.  SUBCLASSES OF HUMAN GAMMA-2-GLOBULIN BASED ON DIFFERENCES IN THE HEAVY POLYPEPTIDE CHAINS.

Authors:  W D TERRY; J L FAHEY
Journal:  Science       Date:  1964-10-16       Impact factor: 47.728

10.  Structural studies of human gamma-G-myeloma proteins of different antigenic subgroups and genetic specificities.

Authors:  B Frangione; E C Franklin; H H Fudenberg; M E Koshland
Journal:  J Exp Med       Date:  1966-10-01       Impact factor: 14.307

View more
  30 in total

1.  Compartmental tissue distribution of antibody therapeutics: experimental approaches and interpretations.

Authors:  C Andrew Boswell; Daniela Bumbaca; Paul J Fielder; Leslie A Khawli
Journal:  AAPS J       Date:  2012-05-31       Impact factor: 4.009

Review 2.  Endoglin-targeted cancer therapy.

Authors:  Ben K Seon; Akinao Haba; Fumihiko Matsuno; Norihiko Takahashi; Masanori Tsujie; Xinwei She; Naoko Harada; Shima Uneda; Tomoko Tsujie; Hirofumi Toi; Hilda Tsai; Yuro Haruta
Journal:  Curr Drug Deliv       Date:  2011-01       Impact factor: 2.565

3.  Metabolism of autologous and homologous IgG in rheumatoid arthritis.

Authors:  M A Catalano; E H Krick; D H De Heer; R M Nakamura; A N Theofilopoulos; J H Vaughan
Journal:  J Clin Invest       Date:  1977-08       Impact factor: 14.808

4.  IgG subclass distribution of anti-Rh, anti-Kell and anti-Duffy antibodies measured by sensitive haemagglutination assays.

Authors:  T E Michaelsen; L Kornstad
Journal:  Clin Exp Immunol       Date:  1987-03       Impact factor: 4.330

5.  Qualitative and quantitative studies on IgG2 globulins in individual human sera with an antiserum capable of differentiating between Gm(n+) and Gm(n-) proteins.

Authors:  M van der Giessen; W Freyee; E Rossouw; E van Loghem
Journal:  Clin Exp Immunol       Date:  1973-05       Impact factor: 4.330

6.  Metabolic properties of human IgA subclasses.

Authors:  A Morell; F Skvaril; G Noseda; S Barandun
Journal:  Clin Exp Immunol       Date:  1973-04       Impact factor: 4.330

7.  Degradation of IgG3 monoclonal proteins during storage and in the presence of a thiol (DL-penicillamine).

Authors:  G Virella
Journal:  Experientia       Date:  1971-01-15

8.  Half-life of the maternal IgG1 allotype in infants.

Authors:  H Sarvas; I Seppälä; S Kurikka; R Siegberg; O Mäkelä
Journal:  J Clin Immunol       Date:  1993-03       Impact factor: 8.317

9.  Human myeloma IgG half-molecules. Catabolism and biological properties.

Authors:  H L Spiegelberg
Journal:  J Clin Invest       Date:  1975-09       Impact factor: 14.808

10.  Metabolic properties of IgG subclasses in man.

Authors:  A Morell; W D Terry; T A Waldmann
Journal:  J Clin Invest       Date:  1970-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.